Literature DB >> 14694037

Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities.

R Feldmann1, J Denecke, M Grenzebach, G Schuierer, J Weglage.   

Abstract

BACKGROUND: Cognitive impairment and fine motor deficits are frequent manifestations in patients with neurofibromatosis type 1 (NF1). More than 50% of patients with NF1 show focal areas of high signal intensity (T2H) on T2-weighted MRI of the brain. It has been hypothesized that T2H may be associated with the cognitive and motor problems.
METHODS: The authors investigated 100 patients with NF1 and 100 healthy control subjects matched for age, sex, and socioeconomic status for their IQ (Wechsler Intelligence Scale for Children-Revised [WISC-R] and Wechsler Adult Intelligence Scale-Revised [WAIS-R]), fine motor abilities (Motorische Leistungs-Serie [motor performance task]), and T2H (MRI).
RESULTS: As a group, the 100 patients performed within normal limits of WISC-R and WAIS-R scores. However, the scores for the NF1 patients with normal MRI were at the mean, whereas those for the patients who had T2H (n = 58) were significantly depressed. On measures of fine motor skills, patients with T2H performed poorer than patients with normal MRI.
CONCLUSION: Hyperintensities on T2-weighted MRI represent a biological marker for impaired cognitive and fine motor performance in patients with NF1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14694037     DOI: 10.1212/01.wnl.0000098881.95854.5f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning.

Authors:  Shelley L Hyman; Deepak S Gill; Edwin Arthur Shores; Adam Steinberg; Kathryn N North
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-13       Impact factor: 10.154

Review 3.  A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1.

Authors:  Andrew J D Crow; Jennica M Janssen; Carolina Marshall; Anne Moffit; Laura Brennan; Christian G Kohler; David R Roalf; Paul J Moberg
Journal:  Am J Med Genet A       Date:  2022-05-12       Impact factor: 2.578

4.  Visuospatial processing in children with neurofibromatosis type 1.

Authors:  Amy M Clements-Stephens; Sheryl L Rimrodt; Pooja Gaur; Laurie E Cutting
Journal:  Neuropsychologia       Date:  2007-10-02       Impact factor: 3.139

5.  Neurobehavioral profiles in individuals with hyperimmunoglobulin E Syndrome (HIES) and brain white matter hyperintensities.

Authors:  Staci Martin; Pamela Wolters; Nia Billings; Mary Anne Toledo-Tamula; Dima A Hammoud; Pamela Welch; Dirk Darnell; Steven M Holland; Alexandra F Freeman
Journal:  J Clin Immunol       Date:  2013-08-21       Impact factor: 8.317

6.  Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.

Authors:  Lianne C Krab; Arja de Goede-Bolder; Femke K Aarsen; Saskia M F Pluijm; Marlies J Bouman; Jos N van der Geest; Maarten Lequin; Coriene E Catsman; Willem Frans M Arts; Steven A Kushner; Alcino J Silva; Chris I de Zeeuw; Henriëtte A Moll; Ype Elgersma
Journal:  JAMA       Date:  2008-07-16       Impact factor: 56.272

7.  NF1 is a critical regulator of muscle development and metabolism.

Authors:  Kate Sullivan; Jad El-Hoss; Kate G R Quinlan; Nikita Deo; Fleur Garton; Jane T C Seto; Marie Gdalevitch; Nigel Turner; Gregory J Cooney; Mateusz Kolanczyk; Kathryn N North; David G Little; Aaron Schindeler
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

8.  Motor learning in children with neurofibromatosis type I.

Authors:  Lianne C Krab; Arja de Goede-Bolder; Femke K Aarsen; Henriëtte A Moll; Chris I De Zeeuw; Ype Elgersma; Josef N van der Geest
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

9.  Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.

Authors:  Jennifer L Griffith; Stephanie M Morris; Jasia Mahdi; Manu S Goyal; Tamara Hershey; David H Gutmann
Journal:  Neurol Clin Pract       Date:  2018-08

10.  Gyrification, cortical and subcortical morphometry in neurofibromatosis type 1: an uneven profile of developmental abnormalities.

Authors:  Inês R Violante; Maria J Ribeiro; Eduardo D Silva; Miguel Castelo-Branco
Journal:  J Neurodev Disord       Date:  2013-02-13       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.